$ Value
$4.7M
Shares
19,241
Price
$243
Filed
Feb 18
Insider
Name
Wolk Joseph J
Title
Exec VP, CFO
CIK
0001744564
Roles
Transaction Details
Transaction Date
2026-02-17
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
38,961
Footnotes
Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. | Shares withheld for payment of taxes upon vesting of PSUs. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. | Shares withheld for payment of taxes upon vesting of RSUs. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. | This transaction was executed in multiple trades at prices ranging from $242.94 to $243.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | This transaction was executed in multiple trades at prices ranging from $242.85 to $242.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | This transaction was executed in multiple trades at prices ranging from $242.71 to $242.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | This transaction was executed in multiple trades at prices ranging from $242.59 to $242.815. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | Held in a spousal lifetime access trust, of which the reporting person's spouse is the trustee and beneficiary. | Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (1/31/2026). | Each RSU represents a contingent right to receive one share of Company Common Stock. | Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. | Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable one day after the third anniversary of the grant date.
Filing Info
Wolk Joseph J's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-17 | JNJ | M | $2.2M |
| 2026-02-17 | JNJ | ▼ | $4.7M |
| 2026-02-17 | JNJ | M | $1.6M |
| 2026-02-17 | JNJ | ▼ | $2.9M |
| 2026-02-17 | JNJ | M | $4.4M |
| 2026-02-17 | JNJ | ▼ | $8.1M |
| 2026-02-17 | JNJ | ▼ | $6.1M |
| 2026-02-17 | JNJ | M | $0 |
| 2026-02-17 | JNJ | M | $0 |
| 2026-02-17 | JNJ | M | $0 |
Other Insiders at JNJ (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
REED JOHN C
EVP, Innovative Medicine, R&D
|
— | $13.1M | 2026-02-17 |
|
Duato Joaquin
CEO and Chairman of the Board
|
— | $22.1M | 2026-02-15 |
|
Wolk Joseph J
Exec VP, CFO
|
— | $17.1M | 2026-02-17 |
|
Taubert Jennifer L
EVP, WWC. Innovative Medicine
|
— | — | 2026-02-15 |
|
Wengel Kathryn E
EVP, Chief TO and Risk Officer
|
— | — | 2026-02-15 |
|
Decker Robert J
VP Corporate Controller
|
— | — | 2026-02-15 |
|
Swanson James D.
EVP, CIO
|
— | $15.1M | 2026-02-17 |
|
Broadhurst Vanessa
EVP, Global Corp Affairs
|
— | $1.5M | 2026-02-17 |
|
Forminard Elizabeth
EVP, Chief Legal Officer
|
— | — | 2026-02-15 |
|
Schmid Timothy
EVP, WW Chair, MedTech
|
— | $5.9M | 2026-02-20 |
|
Mulholland Kristen
EVP, Chief HR Officer
|
— | — | 2026-02-15 |